|Day Low/High||144.72 / 147.45|
|52 Wk Low/High||106.11 / 153.30|
A video of what's changed in the thirty plus years since the last eclipse
As McKesson shows, not every good company is priced to perfection.
(Please be aware that all of the following quotes are rapidly changing as more information becomes available.) Salesforce.com is trading slightly higher after hours after reporting 28 cents (adjusted) vs. 26 cents (forecast). Salesforce is trading ...
You need to see where the health services giant normally trades to appreciate how undervalued it is.
Demographics will continue to favor health-care and pharmaceutical companies.
The markets started the day like Usain Bolt at the start of a 100-meter race. But, unlike Bolt, the finish wasn't as strong as the start. I thought one of the day's features was the reversal in bond yields, particularly after the good data. The...
Apple, Energen and McKesson are among the top stock picks of Mizuho's analysts for 2017.
"Everyone here likes the bounce." -- President-elect Donald Trump (said in a meeting today at Trump Tower with tech executives) A good day for the ursine crowd but not so good for the bullish cabal as they had a bad day -- for a change. (Yes, I am w...
Current valuations are at record lows, despite the companies having good prospects.
Since the election, big questions remain about investing in hospital and healthcare stocks, and the group will remain volatile according to Mizuho.
"Today I am asking myself ... Did the FANG names just peak the way iShares NASDAQ Biotechnology Index ETF IBB did in 2015 and Energy Select Sector SPDR ETFXLE did in 2014? The S&P 500 Index kept rising, but those two groups were done!" -- Kass Diar...
Stocks in the health care sector seem to have no underpinnings whatsoever.
I have been warning about weakening breadth and narrow leadership for weeks and months. What have we gotten? Eight straight days (in a row) down for the first time since 2008. But, with stocks suffering from election uncertainties and given the ...
Shares are trading at less than 12.5x 2017's EPS estimates and should rise soon.
Investors rush to buy the drugmaker's stock following chatter of a much-needed megadeal.
Today there was a virtual vacuum of good news in the stock market.
Jim Cramer says there are other reasons not to buy Valeant, other than the criminal investigation.
Pfizer shares were slipping after the drugmaker posted a premarket earnings whiff.